UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2021

C4 THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-39567**	**47-5617627**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
490 Arsenal Way, Suite 200 **Watertown, MA** **(Address of Principal Executive Offices)**		**02472** **(Zip Code)**

Registrant's Telephone Number, Including Area Code: (617) 231-0700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CCCC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition Regulation FD Disclosure

On January 12, 2021, C4 Therapeutics, Inc. (the "Company") posted a presentation to its website at https://ir.c4therapeutics.com/events-presentations that it expects to share with investors on or before January 14, 2021 in connection with the 39th Annual J.P. Morgan Healthcare Conference. On January 6, 2021, the Company issued a press release announcing its key milestones for 2021. In both the presentation and the press release, the Company disclosed that its unaudited cash, cash equivalents and short-term investments as of December 31, 2020 were approximately $370 million. A copy of the presentation is furnished herewith as Exhibit 99.1 and a copy of the applicable disclosure from the press release is furnished herewith as Exhibit 99.2.

The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2020 and its results of operations for the three months and year ended December 31, 2020. The audit of the Company's consolidated financial statements for the year ended December 31, 2020 is ongoing and could result in changes to the information set forth above.

Item 7.01 Regulation FD Disclosure

The contents of Item 2.02 of this Current Report on Form 8-K are incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number	Description
99.1	Presentation of the Company dated January 2021 (furnished herewith)
99.2	Disclosure on Cash, Cash Equivalents and Short-Term Investments (furnished herewith)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

C4 Therapeutics, Inc.

Date: January 12, 2021

By: /s/ Andrew J. Hirsch
Andrew J. Hirsch
President and Chief Executive Officer

Exhibit 99.1

C4 Therapeutics

Corporate Presentation

January 2021

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.’s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and overseas, including, without limitation, C4 THERAPEUTICS, TORPEDO, BIDAC and MONODAC. All trademarks or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

Targeted Protein Degradation Has the Potential to Transform Treatment of Disease

<15%

Of Human Proteome Addressable by Small Molecule Inhibitors

Substantial opportunity to develop treatments for targets previously considered undruggable

Adapted from Wagle et al, J Clin Oncol, 2011

Cancers become resistant to standard therapies and treatment options are then limited

$63B

2018 Global Revenue

Oncology small molecule therapies generate significant revenue despite known limitations

Targeted Protein Degradation Has Potential to Drug the Remaining ~85% of the Human Proteome and Overcome Resistance to Existing Inhibitor Medicines

Sources: Hopkins, A., Groom, C. The druggable genome. Nat Rev Drug Discov 1, 727–730 (2002). https://doi.org/10.1038/nrd892; "A view on drug resistance in cancer" Nature | Vol 575 | 14 November 2019; Fact.MR: https://www.factmr.com/report/3747/oncology-small-molecule-drugs-market

C4T is Well Positioned to Develop Targeted Protein Degradation Medicines to Transform Patient Care

*12/31/20 unaudited cash balance of approximately $370M

The Human Body Has A Natural Process to Destroy Unwanted Proteins



C4 Therapeutics

Targeted Protein Degradation Leverages the Body's Natural Process to Destroy Disease-Causing Proteins



Targeted Protein Degradation Offers Fundamental Advantages Over Protein Inhibition

1. **Improved Potency**
2. **Fast Response**
3. **High Selectivity**
4. **Expansive Target Landscape**



TORPEDO (Target ORiented ProtEin Degrader Optimizer) Platform

Our TORPEDO Platform Has Potential to Efficiently Design Highly Potent Targeted Protein Degrader Medicines

Elements	Benefits
Ability to Develop both MonoDACs & BiDACS	Flexibility to address different targets with tailored approach
Focus on Catalytic Efficiency	Optimization of overall degradation process results in maximal efficacy
Ability to Design, Analyze & Predict Degrader Performance	Rapid delivery of potent drug candidates through informed and efficient drug discovery
Investment in Cereblon as E3 Ligase	Cereblon is expressed in all tissues and cellular compartments, thereby providing the largest target selection opportunity

TORPEDO Platform Offers Flexibility to Design MonoDACs and BiDACs



Flexibility to Address Different Targets with Tailored Approach

Enhanced Catalytic Activity Drives Efficacy

Improved Catalytic Activity of Degrader A…



…Drives Significant Improvement in Target Knockdown



Source: C4T data on file

TORPEDO Platform: Robust Drug Discovery Process Enabling Higher Confidence in *In Vivo* Efficacy

Design

Computational method incorporates experimental data to identify top models

Atomic-level degrader design utilized to improve selectivity and potency

Analyze

Cellular degradation data fitted using an enzymology framework

Key parameters describe intrinsic degradation activity

Predict

Universal modeling framework merges degradation activity with degrader exposure

Robust predictions of depth and duration of *in vivo* target degradation at any dose

Rapid Delivery of Potent Drug Candidates Through Informed and Efficient Drug Discovery

TORPEDO is Based on a Deep Focus on Cereblon, Providing the Largest Target Selection Opportunity

Cereblon E3 Ligase



- Cereblon, harnessed by IMiDs, is the only clinically validated ligase for targeted protein degradation
- Cereblon is expressed in all tissues and in all cellular compartments
- Investment in rich toolkit of intellectual property with 14 structurally distinct Cereblon binders
- C4T's binders enable drug discovery with enhanced oral bioavailability, solubility, permeability & stability

Programs Benefit from Desirable Properties of C4T's Cereblon Binders

TORPEDO Platform Has Delivered a Robust Degrader Pipeline; Four Clinical Programs Expected by End of 2022

Target	Indication(s)	Discovery	Preclinical	Clinical	Ownership
IKZF1/3 (CFT7455)	Multiple Myeloma & Lymphoma			●	C4 Therapeutics
BRD9 (CFT8634)	Synovial Sarcoma & SMARCB1 Deleted Tumors			●	C4 Therapeutics
BRAF V600E	Drug-Resistant BRAF mutant Melanoma & NSCLC		●		C4 Therapeutics, Roche
RET	Drug-Resistant RET-Altered Tumors		●		C4 Therapeutics
EGFR	Drug-Resistant EGFR+ NSCLC		●		C4 Therapeutics
Transcriptional Control	Undisclosed Solid Tumors	●			C4 Therapeutics
Cancer Signaling	Undisclosed Cancers	●			C4 Therapeutics
Transcriptional Control	Undisclosed Liquid Tumors	●			C4 Therapeutics
Cancer Signaling	Undisclosed Solid Tumors	●			C4 Therapeutics

9 Additional Undisclosed Collaborator Programs in Discovery

Three Strategic Target Platform Collaborations Expand Platform Potential

IKZF1/3
CFT7455

IKZF1/3: Maximal Catalytic Activity Leads to Improved Efficacy

Strong Rationale for Degrader Approach

- Multiple myeloma (MM) and Non-Hodgkin's lymphomas (NHLs) are dependent on IKZF1/3
- Existing IKZF1/3 degraders have limited potency

Clear Unmet Need

- Patients progress on approved IMiD therapies
- Approved IMiDs have limited activity in NHLs

Defined Patient Populations

- MM: ~32K cases/year; median 5-year overall survival (OS): 52%
- NHL: ~77K cases/year
- PTCL: ~4% of all NHLs; median 5-year OS: 20-32%
- MCL: ~7% of all NHLs; median OS: 4-5 years

Compelling Development Opportunity

- Potential for accelerated approval in select indications
- Opportunity to expand into earlier lines of MM therapy

Source: NIH SEER Database, Primary Literature Consensus

Patient figures represent estimated U.S. annual incidence
PTCL = peripheral T-cell lymphoma; MCL = mantle cell lymphoma

CFT7455 Demonstrates Improved Efficacy Compared to Both Approved and Most Advanced Development-stage IKZF1/3 Degraders

CFT7455 *In Vivo* Efficacy – Complete Regression in MM Model



CFT7455 *In Vivo* Efficacy Durable After End of Dosing Period



Source: C4T data on file

CFT7455 Demonstrates Tumor Regression in Multiple Myeloma Xenograft Insensitive to Pomalidomide

CFT7455 Active in RPMI-8226, Relative to Pomalidomide



CFT7455 Active in RPMI-8226 After Tumor Progression on Pomalidomide Treatment



Source: C4T data on file

CFT7455 Phase 1/2 Trial Design Offers Potential for Accelerated Approval Across Three Indications



IND Submitted December 2020; Trial Expected to Initiate in 1H 2021

(1) 28-day cycle / dose limiting toxicity (DLT) window; (2) Combination therapy cohorts will open once each CFT7455 dose level has been cleared for safety

BRD9
CFT8634

BRD9: Drugging the Undruggable with a Degrader Approach

Strong Rationale for Degrader Approach

- Synovial sarcoma (SS) is dependent on BRD9, which is caused by the oncogenic SS18-SSX translocation
- Oncogenicity of BRD9 depends on sub-domains not addressed by traditional inhibitors

Clear Unmet Need

- Very limited benefit of treatments for metastatic or advanced SS – median survival ~18 months

Defined Patient Populations

- SS: ~900 cases/year
- ~10% of all soft tissue sarcomas

Compelling Development Opportunity

- Well defined path to registration in SS and metastatic population already under management at academic centers
- Precedent for approval with a single-arm study in second-line setting

Source: NIH SEER Database, Primary Literature Consensus

Patient figures represent estimated U.S. annual incidence

BRD9 Dependency in Synovial Sarcoma

Mechanistic Rationale



Leveraging a protein degrader approach enables us to effectively target BRD9 since our degraders do not require the binding site to be specifically at the physiologically active domain.



Advantages of BRD9 degradation

- Specifically degrades BRD9 and spares BRD4 and BRD7, avoiding potential off-target toxicities
- Oncogenicity of BRD9 depends on sub-domains not addressed by traditional inhibitors

Robust Responses of CFT8634 Seen in Preclinical Synovial Sarcoma Models

Dose Response Activity
Yamato Xenograft Model



Dose Response Activity
Patient Derived Xenograft Model



IND Submission for CFT8634 Expected in 2H 2021

Source: C4T data on file

BRAF

BRAF: Utilizing a Degrader Approach to Overcome Resistance Mutations

Strong Rationale for Degrader Approach

- Approved BRAF inhibitors cause paradoxical RAF activation, which may result in diminished efficacy
- Potential for degraders to effect deeper elimination of mutant BRAF signaling and create more durable response

Clear Unmet Need

- BRAF mutations occur in ~15% of all cancers
- ~70% - 90% of BRAF mutations are V600E
- Resistance to three approved BRAF inhibitors emerges through multiple paths, resulting in a median PFS of <15 months

Defined Patient Populations

- >70K annual incidence across melanoma, NSCLC, colorectal cancer (CRC) and other malignancies
- 50% of late-stage melanoma
- 1-2% of NSCLC
- 10-20% of CRC
- 50% of papillary thyroid cancer
- 100% of hairy cell leukemia
- >50% of Langerhans cell histiocytosis (LCH)

Compelling Development Opportunity

- Large patient population defined by failure of available BRAF inhibitors
- Target Population: V600E melanoma and/or NSCLC after failure of MEK inhibitor + BRAF inhibitor with indication specific expansion opportunities

Source: NIH SEER Database, Primary Literature Consensus

Patient figures represent estimated U.S. annual incidence

BRAF program is partnered with Roche

BRAF Degrader to Overcome Limitations of Approved BRAF Inhibitors

Mechanistic Rationale



Advantages of BRAF V600E Degradation

- Specifically target mutant BRAF over wildtype BRAF
- Prevent mutant BRAF incorporation into RAF dimers
- Avoid paradoxical activation and associated failure of therapy due to resistance mechanisms dependent on BRAF inhibitor mediated paradoxical activation

BRAF program is partnered with Roche

BRAF Degraders Show Superior Efficacy Compared to Approved BRAF Inhibitors

C4T BRAF Degrader Shows More Durable Efficacy Than Encorafenib



C4T BRAF Degrader Shows More Durable Efficacy Than Dabrafenib



IND Enabling Studies Planned for 2021

Source: C4T data on file

BRAF program is partnered with Roche

RET

RET Degradation: Opportunity to Overcome Resistance Mutations

Strong Rationale for Degrader Approach

- RET is a receptor tyrosine kinase (RTK) that plays a role in normal development but can cause cancer when mutated
- Resistance develops to approved RET inhibitors due to mechanisms including new RET mutations, which make inhibitors inactive

Clear Unmet Need

- No effective targeted therapy after failure of approved first-line RET inhibitors

Defined Patient Populations

- ~10K annual incidence of RET-driven disease across lung, thyroid, and other cancers
- 1-2% of NSCLC
- 60% of sporadic medullary thyroid cancer

Compelling Development Opportunity

- Well defined registration path in existing, genetically defined patient population with no effective treatment option after RET tyrosine kinase inhibition (TKI)
- Target Population: second line RET-altered cancers; potential for front-line opportunity

Sources: NIH SEER Database, https://pubmed.ncbi.nlm.nih.gov/29284153/, Primary Literature Consensus

Patient figures represent estimated U.S. annual incidence

RET Degradation May Have Improved Activity Compared to Best-In-Class RET Inhibitors



Advantages of RET Degradation

- RET degrader is active against key secondary mutations that cause resistance, including both the gatekeeper and solvent front mutations
- Against RET without secondary mutation, as in the front-line setting, degradation may offer deeper and more durable response than inhibition

RET Degrader Has an Excellent Cell Growth Inhibition Profile In RET Fusions and Common Resistance Mutations

Drug Naïve, Driver Translocation/Mutation

KIF5B-RET Fusion



Activating Mutation



RET Inhibitor Acquired-Resistance Mutants

Solvent Front Mutation



Gatekeeper Mutation



Pralsetinib Selpercatinib 2nd Gen RET TKI CFT RET Degrader

IND Enabling Studies Planned for 2021

Source: C4T data on file

C4 Therapeutics

Lead Programs Offer Compelling Opportunities to Address Unmet Need in Multiple Patient Populations

IKZF1/3 CFT7455

NON-HODGKIN's LYMPHOMA
77K cases/year

32K cases/year
MULTIPLE MYELOMA

5-year survival
52%

BRD9 CFT8634

SYNOVIAL SARCOMA
900
cases/year

MEDIAN PFS OF 1L CHEMOTHERAPY
6.3
months

BRAF BiDAC

>70K
cases/year

MELANOMA, NSCLC, CRC AND OTHER MALIGNANCIES

PFS across approved BRAF inhibitors
<15
months

RET BiDAC

1-2%
of NSCLC

median **PFS**
~16.5
months
(selpercatinib)

60%
of sporadic medullary thyroid cancer

Sources: National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Database
MM survival: https://seer.cancer.gov/archive/csr/1975_2015/browse_csr.php?sectionSEL=18&pageSEL=sect_18_table.08.html#table2_ SS PFS: M. Vlenterie et al. European Journal of Cancer 58 (2016) 62e72; BRAF PFS: Cell Press Review, Trends in Cancer, September 2020, Vol. 6, No. 9; RET PFS: NJEM 383;9 nejm.org 8/27/20

Patient figures represent estimated U.S. annual incidence

2021 Milestones Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

	2021	2022
IKZF1/3 (CFT7455)	❑ Phase 1/2 Initiation	❑ Phase 1 Top-line Safety & Efficacy ❑ Proof of Mechanism
BRD9 (CFT8634)	❑ IND Submission	❑ Phase 1 Initiation
BRAF	❑ IND Enabling Studies	❑ Phase 1 Initiation
RET	❑ IND Enabling Studies	❑ Phase 1 Initiation

C4T is Well Positioned to Develop Targeted Protein Degradation Medicines to Transform Patient Care

*12/31/20 unaudited cash balance of approximately $370M

C4 Therapeutics

Thank You

Exhibit 99.2

Cash Guidance

Unaudited cash, cash equivalents and short-term investments as of December 31, 2020, were approximately $370 million. C4 Therapeutics, Inc. expects its cash, cash equivalents and short-term investments, including payments anticipated to be received under existing collaboration agreements, will be sufficient to fund its operating plan to the end of 2023.

ACTIVE/106555018.1